Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.
Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation
Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...
DOI: 10.1016/j.jad.2026.121208 (opens in new tab)
Full text (opens in new tab)
Esketamine
Mdd
Treatment-resistant depression
Intranasal racemic ketamine
+1